Wealth Enhancement Advisory Services LLC Lowers Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Wealth Enhancement Advisory Services LLC decreased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 53.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 66,842 shares of the biotechnology company's stock after selling 76,705 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Exelixis were worth $2,226,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of EXEL. Vanguard Group Inc. lifted its position in shares of Exelixis by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company's stock worth $979,994,000 after purchasing an additional 121,750 shares during the last quarter. LSV Asset Management raised its stake in Exelixis by 0.8% in the fourth quarter. LSV Asset Management now owns 8,169,847 shares of the biotechnology company's stock valued at $272,056,000 after buying an additional 67,470 shares in the last quarter. Fuller & Thaler Asset Management Inc. raised its stake in Exelixis by 10.2% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 7,630,940 shares of the biotechnology company's stock valued at $254,110,000 after buying an additional 708,312 shares in the last quarter. Invesco Ltd. lifted its holdings in Exelixis by 308.1% during the 4th quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company's stock worth $132,376,000 after buying an additional 3,001,204 shares during the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Exelixis by 25.7% during the 4th quarter. AQR Capital Management LLC now owns 3,967,005 shares of the biotechnology company's stock worth $132,101,000 after acquiring an additional 810,857 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on EXEL. Royal Bank of Canada restated an "outperform" rating and set a $40.00 target price on shares of Exelixis in a research note on Wednesday, May 14th. Wall Street Zen cut shares of Exelixis from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 15th. Wells Fargo & Company reissued a "market outperform" rating on shares of Exelixis in a research report on Thursday, April 17th. UBS Group reissued an "underperform" rating on shares of Exelixis in a report on Thursday, April 17th. Finally, Bank of America raised their price target on Exelixis from $45.00 to $46.00 and gave the stock a "neutral" rating in a report on Thursday. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, Exelixis has an average rating of "Moderate Buy" and a consensus price target of $39.35.

Exelixis Trading Down 0.3%

Shares of NASDAQ:EXEL traded down $0.11 during trading on Monday, hitting $42.92. 2,418,970 shares of the stock were exchanged, compared to its average volume of 2,339,281. The company has a fifty day moving average price of $39.03 and a two-hundred day moving average price of $36.67. The company has a market cap of $11.70 billion, a PE ratio of 24.25, a P/E/G ratio of 1.13 and a beta of 0.28. Exelixis, Inc. has a 12-month low of $21.36 and a 12-month high of $48.85.

Insider Buying and Selling

In other Exelixis news, CMO Amy C. Peterson sold 72,776 shares of Exelixis stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $45.47, for a total value of $3,309,124.72. Following the completion of the sale, the chief marketing officer now directly owns 465,393 shares of the company's stock, valued at approximately $21,161,419.71. The trade was a 13.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Christopher J. Senner sold 100,000 shares of the business's stock in a transaction on Friday, May 16th. The shares were sold at an average price of $46.00, for a total value of $4,600,000.00. Following the completion of the transaction, the chief financial officer now owns 967,842 shares of the company's stock, valued at $44,520,732. This trade represents a 9.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 458,113 shares of company stock worth $21,024,817 in the last ninety days. Insiders own 2.82% of the company's stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.